Search Within

Even Holth Rustad

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (9)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies Research (19)
  4. Hematologic Malignancies, Division of (19)
  5. Myeloma (19)
  6. Sloan Kettering Institute Postdocs (19)

More Groups

People
  1. Malin Hultcrantz (19)
  2. Carl Landgren (18)
  3. Sham Mailankody (16)
  4. Neha Korde (15)
  5. Venkata Yellapantula (14)
  6. Heather Landau (13)

More People

Years
  1. 2021 (3)
  2. 2020 (5)
  3. 2019 (8)
  4. 2018 (3)
Publications
  1. Blood (9)
  2. Blood Cancer Journal (2)
  3. JAMA Oncology (2)
  4. American Journal of Hematology (1)
  5. British Journal of Haematology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. Nature Publishing Group (3)
  3. American Medical Association (2)
  4. American Association for Cancer Research (1)
  5. American Society of Clinical Oncology (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Journal Article

    Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Meeting Abstract

    Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Accelerated single cell seeding in relapsed multiple myeloma
    Journal Article

    Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
    Journal Article

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save